Outcome of Follicular Lymphoma Grade 3: Is Anthracycline Necessary as Front-Line Therapy?
Author Information
Author(s): Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman A R, Jain P, Bishop L, Horwich A, Catovsky D
Primary Institution: Royal Marsden Hospital
Hypothesis
Is anthracycline necessary as front-line therapy for patients with follicular lymphoma grade 3?
Conclusion
Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy for patients with follicular lymphoma grade 3.
Supporting Evidence
- Overall survival rates at 10 years were 69.2% for grade 3 patients.
- No survival differences were observed among grades 1, 2, and 3.
- Patients with FL grade 3 had a continuing risk of relapses.
Takeaway
This study looked at patients with a type of blood cancer called follicular lymphoma grade 3 and found that using a specific type of chemotherapy called anthracycline didn't help them live longer or avoid relapses.
Methodology
The study followed 215 patients with follicular lymphoma grade 3, comparing their survival based on treatment types and grading.
Limitations
The study had a small number of patients with grade 3b and lacked multivariate analysis due to limited events.
Participant Demographics
Patients included 55 with grade 3 FL, with a median age of 53 years.
Statistical Information
P-Value
0.86
Confidence Interval
95% CI=50.2–82.2%
Statistical Significance
p=0.86
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website